HealthcareMid capRs 17,428 crRs 19.0 cr traded a day
Close on 2026-08-21
1,719.40
−2.84%
52-week range60% of the way up
1,191.102,067.00
Market cap
17,428 cr
P/E (TTM)
55.7×
industry 44×
EPS (TTM)
30.87
Revenue YoY
+30.3%
Q1 FY27
Profit YoY
-8.4%
Net margin
16.2%
-6.9pt vs a year ago
Growth trend
+9.0pt
vs last quarter’s YoY
1 month
+5.5%
Below 52w high
20.2%
RSI (14)
49
Daily swing
3.8%
average true range
Volume
0.5×
vs 20-day average
Traded
Rs 19 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−3.74%
1 month
+5.47%
3 months
+19.42%
6 months
+36.60%
1 year
−17.24%
The read
written from the numbers on this page
The evidence is mixed3 supporting, 3 against, 0 worth knowing
Supporting
trading 9% above its 200-day average
3 independent kinds of evidence agree today, which is uncommon
revenue grew 30% year on year in the quarter ending 2026-06-30
Against
down 17% over twelve months
net margin has narrowed from 20.7% to 16.2% across four quarters
priced at 56× earnings against an industry median of 44× — 27% above its peers
Worth knowing
nothing the data supports either way
What would change this read: a close below 1,578, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
How it has performed
price return over each window, measured against zero
What the scans say today
3 of 47 matched on 2026-08-21
POLYMED matches 3 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 2024-09-06
38×
median 58×
96×
now 56×
POLYMED trades at 56× trailing earnings, close to its median of 58× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 30% against the same quarter a year earlier
net margin widened from 12.2% to 16.2%
revenue rose in 3 of the last 4 quarters
Going against it
profit dropped 8% year on year
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
525
116
85
8.49
16.2%
Q4 FY26
2026-03-31 · consolidated
535
84
65
6.54
12.2%
Q3 FY26
2025-12-31 · consolidated
494
96
71
7.00
14.3%
Q2 FY26
2025-09-30 · consolidated
444
121
92
9.06
20.7%
Q1 FY26
2025-06-30 · consolidated
403
122
93
9.19
23.1%
Q4 FY25
2025-03-31 · consolidated
441
121
92
8.92
20.8%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+2.0%
Versus 200-day average+9.0%
Below 52-week high-16.8%
Above 52-week low+44.4%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)49.1
Higher closes in last 51 of 5
Six-month return+36.60%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.83%
Volume versus 20-day0.5x
Median daily turnoverRs 19.0 cr
Peers
Healthcare · 67 classified companies
POLYMED trades at 55.7× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — more expensive than them, by 27%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.